GlassScriptPhysician profile
Stephen Craig Martin
NPI 1366736019
$699.25
in general payments reported to CMS, 2019-2025
14 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $56.65 · 2022: $33.85 · 2023: $68.40 · 2024: $94.23 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $158.22 | 2019-2025 | Hemgenix |
| Bayer Healthcare Pharmaceuticals INC. | $99.67 | 2019-2025 | |
| Novo Nordisk INC | $65.61 | 2020-2025 | Alhemo |
| Genzyme Corporation | $57.17 | 2022-2024 | |
| Pierre Fabre Pharmaceuticals, INC. | $57.14 | 2023-2025 | Hemangeol |
| Jazz Pharmaceuticals INC. | $51.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.72 | 2019 | |
| Alexion Pharmaceuticals, INC. | $36.67 | 2023-2025 | Ultomiris, Koselugo |
| Adaptive Biotechnologies Corporation | $33.77 | 2025 | Clonoseq |
| Pfizer INC. | $26.83 | 2019 | |
| Kedrion Biopharma, INC. | $20.90 | 2025 | Kedrab, Koate, Rhogam Ultra-Filtered Plus |
| Rare Disease Therapeutics, INC. | $18.60 | 2025 | Xromi |
| Y-Mabs Therapeutics, INC. | $17.18 | 2025 | Danyelza |
| Shire North American Group INC | $13.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.